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A B S T R A C T
Sterolomics can be thought of as the quantitative determination of the entire complement of molecules based on
the cyclopentanoperhydrophenanthrene skeleton in a system. Mass spectrometry is the dominant analytical
technology employed. In this article we highlight some pitfalls in analysis, data interpretation and annotation.
We give our opinion on how some of these pitfalls can best be avoided. This article is part of a Special Issue
entitled: BBALIP_Lipidomics Opinion Articles edited by Sepp Kohlwein.
1. Introduction
Based on the Lipidmaps classiﬁcation system [1], sterolomics can be
thought of as the quantitative determination of the entire complement
of molecules built on the cyclopentanoperhydrophenanthrene skeleton
in a cell type, tissue, organ, or body ﬂuid. This deﬁnition includes
oxysterols, hormonal steroids, bile acids and their precursors and
metabolites. The complexity of the sterolome is magniﬁed when the
existence stereochemical isomers is taken into consideration. For
simplicity, in this article we will concentrate on mammalian oxysterols
derived primarily from cholesterol. For those interested in steroid
hormone, bile acid or vitamins D analysis excellent articles can be
found in the textbook “Steroid Analysis” edited by Makin and Gower
[2]. A useful collection of articles more speciﬁcally on steroid hormones
can be found in a 2016 special issue of the Journal Steroid Biochemistry
and Molecular Biology [3] and on vitamins D in another 2016 special
issue of the same journal [4,5]. Clayton and Griﬃths and Sjövall have
written authorities reviews on bile acids and their analysis [6,7].
Mass spectrometry (MS) is the dominant analytical technology
employed in sterolomics. Most sterolomic studies have been performed
on human plasma or serum with fewer studies performed on other
bioﬂuids e.g. cerebrospinal ﬂuid, or tissues e.g. brain [8]. When data is
compared from diﬀerent studies reported in the literature it is
important to establish whether the report refers to “total” sterol levels
where an alkaline hydrolysis step has been performed to hydrolyse
sterols esteriﬁed with fatty acids or whether “free” non-esteriﬁed sterols
are the subject of investigation. In general studies performed using gas
chromatography (GC)–MS include an alkaline hydrolysis step while
those which utilise liquid chromatography (LC)-MS may or may not
include saponiﬁcation. The gold standard methods for oxysterol
analysis is by GC–MS and includes a saponiﬁcation step [9].
2. Experimentation
For oxysterol analysis nearly all methods require an extraction step
followed by a separation step. The most popular extraction methods are
based on Folch-like extractions using methanol and chlorinated sol-
vents, however, our preference is for the single-phase extraction of non-
esteriﬁed oxysterols is into ethanol, which will also extract oxysterols
esteriﬁed with sulphuric acid or acetal linked sugars [8,10]. The choice
of extraction solvents should be made based on any subsequent
requirement for a saponiﬁcation step and the stability of the target
analytes. Oxysterols with a 7-hydroxy-3-oxo-4-ene function are labile
and will dehydrate in basic solutions, while oxysterols derived from 7-
dehydrocholesterol (7-DHC) with a 5,7-diene structure are also suscep-
tible to reaction in basic solutions. It is important for those new to the
oxysterol ﬁeld to be aware that not only cholesterol, but also its
precursors, particularly desmosterol and 7-DHC can be the parent sterol
from which oxysterols are derived, both in vivo and ex vivo.
A major concern in all oxysterol analysis is uncontrolled ex vivo
reaction of cholesterol, and also desmosterol and 7-DHC, with atmo-
spheric oxygen to generate oxysterols which have similar structures to
those formed in vivo [11,12]. As cholesterol is usually more than 1000
fold more abundant in biological samples than endogenous oxysterols
only a minor degree of ex vivo oxidation can cause extreme confusion
upon data interpretation. 7-DHC is more than 100 times more reactive
towards free radical oxidation than cholesterol and it propensity
towards ex vivo oxidation can be a source of further confusion [13].
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It is imperative to minimise these unwanted events. This is often
achieved by the addition of antioxidants like butylated hydroxytoluene
(BHT) and or triphenylphosphine (TPP) [9,12]. Our preference to avoid
confusion over ex vivo oxidation of cholesterol, 7-DHC and other
sterols, is to separate more polar oxysterols from more hydrophobic
sterols like cholesterol and 7-DHC in the ﬁrst step of sample handling
following extraction [8,10,14]. An eﬃcient method to monitor ex vivo
oxidation during sample handling is to add deuterated cholesterol and/
or 7-DHC during the extraction step and monitor the formation of
deuterated oxysterols [12,15].
To make meaningful biological conclusions based on oxysterol
analysis it is imperative to make quantitative or at least semi-quanti-
tative measurements. This is best performed by the addition of stable-
isotope labelled internal standards during the extraction step [9].
Ideally a labelled analogue should be included for each target analyte.
This may not be possible, in which case an isotope-labelled version of a
structurally similar analyte is the next best option. A major source of
inter-laboratory variability in quantitative measurements, even when
identical methods are employed, can be derived from variability in the
purity of unlabelled standard compounds. The response of the isotope
labelled standard is usually calibrated against known amounts of “pure”
unlabelled compound. But how pure is a “pure” unlabelled compound?
Can the analyst trust the purity indicated by the vendor, which is
perhaps based on thin layer chromatography? Our preference is to
purchase quantitative standards from Avanti Polar Lipids Inc. where
exact amounts of standard are dissolved in a deﬁned volume of solvent
and a certiﬁcate of analysis is provided showing purity data.
Most oxysterol analysis based on GC–MS utilises selected ion
monitoring (SIM) where the intensity of one or just a few ions are
measured and analyte identiﬁcation is dependent on GC retention time.
A similar approach is used in LC–tandem MS (MS/MS) methods where
multiple reaction monitoring (MRM) is employed for detection and LC
separation relied upon for identiﬁcation [16]. These methods are
perfectly valid, but do rely on the earlier analysis of appropriate
standards to deﬁne chromatographic retention times. Problems arise
when there is co-elution of compounds which the analyst is unaware of.
A disadvantage of both SIM and MRM methods is that unexpected
compounds will not be detected unless the appropriate m/z channel is
included. Even if an unexpected compound is detected it cannot be
identiﬁed by SIM or MRM in the absence of an authentic standard. This
problem can be overcome in GC–MS by recording a full scan electron
ionisation mass spectrum which will be rich in structural information.
In LC-MS analysis, our preference it to exploit derivatisation chemistry
which will provide information on functional groups and also to utilise
multistage fragmentation (MSn) to maximise the information provided
by MS [8,10,14].
There are a huge number of isomeric oxysterols, for instance in
human plasma 4β-, 7α-, 7β-, 22R-, 24S-, 25- and (25R)26-hydroxycho-
lesterols are found. The situation is further complicated in cell cultures
where 24R- and (25S)26-isomers can also be present and is much more
complicated for dihydroxycholesterols where there are two sites of
variability. Thus, for secure identiﬁcation and quantiﬁcation, chroma-
tographic separation prior to MS analysis is a pre-requisite. However, if
the analyst is certain of the nature of a dominant oxysterol in a
particular matrix a shotgun method in the absence of chromatography
could be employed e.g. for 24S-hydroxycholesterol in mammalian
brain.
When diﬀerent laboratories analyse the same sample for a pre-
deﬁned list of oxysterols the spread of values determined can be quite
alarming. For example, in 2014 eleven laboratories measured the
“total” 24S-HC content of two serum samples by MS methods, the
mean ± standard deviation values for the two samples were
60.9 ± 36.7 ng/mL and 38.0 ± 21.6 ng/mL. The median values with
the 16%–84% range given in brackets were 57.0 (38.5–78.9) ng/mL
and 33.0 (23.7–48.6) ng/mL [17]. Although, most values clustered
about the median, work still needs to be done to harmonise analytical
methods. Our belief is that inter-laboratory reproducibility will be best
improved by harmonising the use of quantitative standards.
3. Databases
While databases are very useful, they can be very dangerous when
used without careful consideration. Attempting to simply match a
measured mass, however accurately determined, to a compound in a
database can lead to gross misinterpretation of results. This is particu-
larly true in the ﬁeld of oxysterols where multiple isomers exist. By
simply tabulating the arbitrary “top-hit isomer” cannot only mislead the
reader but also cause problems when published data is extracted in an
automated fashion. We recommend the use of the LipidMaps data base
http://www.lipidmaps.org/data/structure/index.html which not only
provides exact mass values, structures in an easily exported form,
systematic names but also InChIKey codes for deﬁning structural
certainty. Links can also be found to other databases such as the
Human Metabolome Data Base (HMDB), LipidBank and KEGG. With
respect to lipid annotation from MS data Liebisch et al. have developed
a hierarchical system for lipid annotation based on structural informa-
tion evident from the analysis [18].
4. Limitations and future challenges
What are the current limitations to oxysterol analysis? As mentioned
above, a major limitation is the discrepancy in inter-laboratory
measurements. We encourage the community, spearheaded by the
European Network for Oxysterol Research (ENOR) to further engage
in quality assessment schemes. Collaboration with a chemical supplier,
such as Avanti Polar Lipids Inc., in a similar manner to that exploited by
the LipidMaps consortium, could be of great beneﬁt in this regard.
A major challenge for researchers analysing oxysterols is to resolve
diﬀerent isomers. When a value is reported for 24S-HC in a biological
sample, is the researcher sure he/she is measuring 24S-HC or a
combination of both 24S- and 24R-isomers? While 24S-HC is undoubt-
edly the dominant isomer in human plasma, the 24R-isomer can be
formed by many diﬀerent primary cells, and is also found in e.g. mouse
plasma [19]. The problem of chromatographically overlapping isomers
can be even more extreme when dihydroxycholesterols are considered.
Despite these words of caution analytical methods based on MS are
continually being reﬁned and improved. A very exciting area of new
research is oxysterol mass spectrometry imaging (MSI). Using deriva-
tisation and MSI it has been possible to localise 7-oxocholesterol in
brain [20].
5. Concluding remarks
Oxysterols were once thought of as uninteresting intermediates in
the metabolism of cholesterol to steroid hormones and bile acids. An
increasing volume of data has now shown that these molecules can be
ligands to nuclear receptors and G protein-coupled receptors and
through binding to the protein INSIG regulate cholesterol biosynthesis
via SREBP-2 [21]. As biologists and clinical scientists become more
aware of oxysterols there becomes a greater demand for their careful
analysis.
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